Urban Paulsson and Stefan K Nilsson, Lipigon

At an Extraordinary General Meeting, Urban Paulsson was elected a regular board member of Umeå-based Lipigon Pharmaceuticals AB. Urban Paulsson’s business law expertise entails a strengthening of the Board and is an important component for the company’s continued successful development.

Urban Paulsson is a lawyer with over 20 years of experience from leading positions and board work in the pharmaceutical sector, including Pharmacia Corporation and Vitrolife. Most recently Urban comes from Camurus AB, where he will be VP Corporate Development until the turn of the year. He also has a number of different board assignments, including in the pharmaceutical company Nanexa, which is listed on Nasdaq First North.
In connection with the election, Paulsson’s investment company invested SEK 3,000,000 in Lipigon.
”We welcome Urban as a new member of Lipigon’s board. With his experience from life science companies in a listed environment, he matches Lipigon’s needs well. In addition, he brings with him a fine track record as both investor and entrepreneur,” says Stefan K Nilsson, CEO of Lipigon.
He continues:
”Urban’s knowledge will be very valuable for Lipigon in our ambitions to establish ourselves as a growth-oriented pharmaceutical company.
Lipigon, which is located at the Umeå Biotech Incubator, develops medicines for lipid-related disorders, i.e. diseases caused by irregularities when fats are processed in the body. Of these the most well-known is cholesterol and the role it plays in the development of cardiovascular disease, but fats can also contribute to various liver diseases, type 2 diabetes and a number of rare so-called ‘orphan drug’ diseases.
For more information, please contact:

Stefan K Nilsson, CEO of Lipigon
+46 70 578 17 68

About Lipigon Pharmaceuticals AB
Lipigon are lipid biology experts focusing on developing novel therapeutics for patients with lipid- related disorders. The company is a spin-off from Umeå University, Sweden, based on five decades of lipid research. Our primary focus is orphan lipid disorders and in addition to the ANGPTL antisense program, Lipigon’s pipeline, including a project for gene therapy treatment of lipodystrophy. This program is partnered with Combigene AB (publ). www.lipigon.se.